Results
1 -
10 of
13Huynh H., Ngo V. C., Fargnoli J., Ayers M., Soo K. C., Koong H. N., Thng C. H., Ong H. S., Chung A., Chow P., Pollock P., Byron S., Tran E..
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma, Clinical Cancer Research, 2008 Bhide Rajeev S., Cai Zhen-Wei, Zhang Yong-Zheng, Qian Ligang, Wei Donna, Barbosa Stephanie, Lombardo Louis J., Borzilleri Robert M., Zheng Xiaoping, Wu Laurence I., Barrish Joel C., Kim Soong-Hoon, Leavitt Kenneth, Mathur Arvind, Leith Leslie, Chao Sam, Wautlet Barri, Mortillo Steven, Jeyaseelan Robert, Kukral Daniel, Hunt John T., Kamath Amrita, Fura Aberra, Vyas Viral, Marathe Punit, D'Arienzo Celia, Derbin George, Fargnoli Joseph.
Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor, Journal of Medicinal Chemistry, 2006 Allen E., Walters I. B., Hanahan D..
Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition, Clinical Cancer Research, 2011 Finn R. S., Kang Y.-K., Mulcahy M., Polite B. N., Lim H. Y., Walters I., Baudelet C., Manekas D., Park J.-W..
Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma, Clinical Cancer Research, 2012 Drug Excipient Interactions, Excipient Applications in Formulation Design and Drug Delivery Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate, Cancer Chemotherapy and Pharmacology Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors, Cancer Chemotherapy and Pharmacology The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases, Cancer Chemotherapy and Pharmacology Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug, Pharmaceutical Research Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate, Breast Cancer Research and Treatment